This is a working overview of WADA prohibited list, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-17 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Letsie I, who succeeded Moshoeshoe in 1870, viewed the annexation as merely a treaty of alliance and protection. Basuto chiefs therefore actively challenged the efforts of British authorities to enact major reforms without prior consultations. On 31 December 1870, Sir Henry Barkly was appointed as the new High Commissioner for Southern Africa. The British had long entertained the idea of incorporating Basutoland into the Cape Colony, and Barkly immediately pushed for annexation on the premise of the financial costs incurred by the colony's policing of Basutoland. The bill confirming the annexation was approved by the Cape Parliament on 11 August 1871.
=== Air spread === An air spread will include the breathing air supply equipment, and often a deck decompression chamber. Where a chamber is present, facilities for hyperbaric oxygen treatment are usually required. If the planned decompression is to be long, a diving stage or bell and the associated handling equipment is likely to be included to allow better control of ascent rate and decompression depth. Equipment for in-water or surface decompression on oxygen (SurDO2) may be available. Equipment may be necessary to facilitate safe entry to and exit from the water, and may include extrication equipment in case the diver is injured. A basic offshore air diving spread will typically include a dive control unit with compressor and high pressure storage banks, a launch and recovery system with a wet bell, a deck decompression chamber and a hot water unit.
The behavior of NAPLs in the subsurface is guided by both the composition of the subsurface material and the various properties of the NAPLs. The subsurface can be categorized into two primary zones: the unsaturated (vadose) zone, which includes small grains or particles surrounded by a thin film of water; and the saturated (phreatic) zone, which contains important storages of groundwater called aquifers. NAPLs are point-source pollutants, and they can be released from a variety of sources, including, but not limited to, improper chemical disposal, leaking underground storage tanks, septic tank effluent, and percolation from spills or landfills. Under high precipitation conditions, liquid will infiltrate the unsaturated zone; if there is enough volume of liquid, it will then percolate into the saturated zone. The porosity of the subsurface environment will determine the quantity that manages to enter the saturated zone.
Sources: en.wikipedia.org
Inflammation of the esophagus is known as esophagitis. Reflux of gastric acids from the stomach, infection, substances ingested (for example, corrosives), some medications (such as bisphosphonates), and food allergies can all lead to esophagitis. Esophageal candidiasis is an infection of the yeast Candida albicans that may occur when a person is immunocompromised. As of 2021 the causes of some forms of esophagitis, such as eosinophilic esophagitis, are not well-characterized, but may include Th2-mediated atopies or genetic factors. There appear to be correlations between eosinophilic esophagitis, asthma (itself with an eosinophilic component), eczema, and allergic rhinitis, though it is not clear whether these conditions contribute to eosinophilic esophagitis or vice versa, or if they are symptoms of mutual underlying factors. Esophagitis can cause painful swallowing and is usually treated by managing the cause of the esophagitis - such as managing reflux or treating infection.
A diagnosis of myocardial infarction is created by integrating the history of the presenting illness and physical examination with electrocardiogram findings and cardiac markers (blood tests for heart muscle cell damage). A coronary angiogram allows visualization of narrowings or obstructions on the heart vessels, and therapeutic measures can follow immediately. At autopsy, a pathologist can diagnose a myocardial infarction based on anatomopathological findings. A chest radiograph and routine blood tests may indicate complications or precipitating causes and are often performed upon arrival to an emergency department. New regional wall motion abnormalities on an echocardiogram are also suggestive of a myocardial infarction. Echo may be performed in equivocal cases by the on-call cardiologist. In stable patients whose symptoms have resolved by the time of evaluation, Technetium (99mTc) sestamibi (i.e. a "MIBI scan"), thallium-201 chloride or Rubidium-82 Chloride can be used in nuclear medicine to visualize areas of reduced blood flow in conjunction with physiologic or pharmacologic stress. Thallium may also be used to determine viability of tissue, distinguishing whether non-functional myocardium is actually dead or merely in a state of hibernation or of being stunned.
Constitutionally, the Soviet Union was a federation. In accordance with provisions present in its Constitution (versions adopted in 1924, 1936 and 1977), each republic retained the right to secede from the USSR. Throughout the Cold War, this right was widely considered to be meaningless; however, the corresponding Article 72 of the 1977 Constitution was used in December 1991 to effectively dissolve the Soviet Union, when Russia, Ukraine, and Belarus seceded from the Union. Although the Union was created under an initial ideological appearance of forming a supranational union, it never de facto functioned as one; an example of the ambiguity is that the Ukrainian Soviet Socialist Republic in the 1930s officially had its own foreign minister, but that office did not exercise any true sovereignty apart from that of the union. The Constitution of the Soviet Union in its various iterations defined the union as a federation with the right of the republics to secede. This constitutional status led to the possibility of the parade of sovereignties once the republic with de facto (albeit not de jure) dominance over the other republics, the Russian one, developed a prevailing political notion asserting that it would be better off if it seceded. The de facto dominance of the Russian republic is the reason that various historians (for example, Dmitri Volkogonov and others) have asserted that the union was a unitary state in fact albeit not in law.
Sources: en.wikipedia.org
The IDF traces its roots to Jewish paramilitary organizations in the New Yishuv, starting with the Second Aliyah (1904 to 1914). The first such organization was Bar-Giora, founded in September 1907. Bar-Giora was transformed into Hashomer in April 1909, which operated until the British Mandate of Palestine came into being in 1920. Hashomer was an elitist organization with narrow scope, and was mainly created to protect against criminal gangs seeking to steal property. The Zion Mule Corps and the Jewish Legion, both part of the British Army of World War I, further bolstered the Yishuv with military experience and manpower, forming the basis for later paramilitary forces. After the 1920 Palestine riots against Jews in April 1920, the Yishuv leadership realised the need for a nationwide underground defense organization, and the Haganah was founded in June of the same year. The Haganah became a full-scale defense force after the 1936–1939 Arab revolt in Palestine with an organized structure, consisting of three main units—the Field Corps, Guard Corps, and the Palmach. During World War II, many Jews from the Yishuv enlisted in the British Armed Forces. Many of them served in the British Army, culminating in the formation of the Jewish Brigade. These would eventually form the backbone of the Israel Defense Forces, and provide it with its initial manpower and doctrine. Following Israel's Declaration of Independence, prime minister and defense minister David Ben-Gurion issued an order for the formation of the Israel Defense Forces on 26 May 1948.
=== Hematopoietic stem cell transplantation === Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for both alpha and beta thalassemia. It involves replacing the dysfunctional stem cells in the bone marrow with healthy cells from a well-matched donor. Cells are ideally sourced from human leukocyte antigen matched relatives; the procedure is more likely to succeed in children rather than adults. The first HSC transplant for thalassemia was carried out in 1981 on a patient with beta thalassemia major. Since then, a number of patients have received bone marrow transplants from healthy matched donors, although this procedure has a high level of risk. In 2018 an unborn child with hydrops fetalis, a potentially fatal complication of alpha thalassemia, was successfully transfused in utero with her mother's stem cells. HSCT is a dangerous procedure with many possible complications; it is reserved for patients with life-threatening diseases. Risks associated with HSCT can include graft-versus host disease, failure of the graft, and other toxicity related to the transplant. In one study of 31 people, the procedure was successful for 22 whose hemoglobin levels improved to the normal range, in seven the graft failed and they continued to live with thalassemia, and two died of transplantation-related causes.
flagellum (pl.) flagella A long, thin, hair-like appendage protruding from the surface of some cells, which serves locomotory functions by undulating in a way that propels the cell through its environment or by effecting the movement of extracellular fluids and solutes past the cell surface. Many unicellular organisms, including some bacteria, protozoa, and algae, bear one or more flagella, and certain cell types in multicellular organisms, namely sperm cells, also have flagella. Eukaryotic flagella are essentially just longer versions of cilia, often up to 150 micrometres (μm) in length, while bacterial flagella are typically smaller and completely different in structure and mechanism of action.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.